EMPEROR-Preserved Cost, Cost-Effectiveness, and Health-Economic Implications
Health-economic analyses of empagliflozin in HFpEF from the EMPEROR-Preserved trial: cost per QALY, payer coverage, list vs net pricing, and individual value calculations.
Trials Empower Rt
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
6articles
3topic areas covered
May 25, 2026latest review
Trials Empower Rt library
Showing 6 of 6 clinical reviews.
EMPEROR-Preserved Extension Data and What Happened After the Trial Ended
Long-term follow-up from the EMPEROR-Preserved trial reveals durable empagliflozin benefits in HFpEF, emerging safety patterns, and unanswered questions about SGLT2 inhibitor therapy beyond the original 26-month median observation.
EMPEROR-Preserved Results in Detail: Numbers, Subgroups, and Time Course
Full breakdown of the EMPEROR-Preserved trial results for empagliflozin in HFpEF, including primary and secondary endpoints, hazard ratios, confidence intervals, time-course patterns, and subgroup analyses.
EMPEROR-Preserved Subgroup Analyses: Who Responded Most and Least
A detailed breakdown of pre-specified and post-hoc subgroup analyses from the EMPEROR-Preserved trial of empagliflozin in HFpEF, examining which patient populations saw the greatest and smallest benefit.
EMPEROR-Preserved Trial: A Plain-English Overview of What It Established
Plain-English breakdown of the EMPEROR-Preserved trial showing empagliflozin reduced CV death and heart failure hospitalization by 21% in patients with HFpEF.
What EMPOWER Actually Changes in Clinical Practice
Deep-dive into the EMPEROR-Preserved trial: how empagliflozin's 21% reduction in CV death or HF hospitalization reshaped guideline recommendations and prescribing for HFpEF patients.